Adalimumab is effective for induction and maintenance of remission in patients with moderate to severe ulcerative colitis (UC).
Dr Brian Feagan and colleagues from Canada assessed whether adalimumab, in addition to standard UC therapy, reduced the risk for hospitalization, and colectomy in patients with moderate to severe UC compared with placebo.
Data were combined from patients that received induction therapy or placebo in 2 trials.
|Lower incidence rates for drug-related hospitalizations were observed during 52 weeks of adalimumab therapy |
The risks of hospitalization and colectomy were compared between groups using unadjusted rates during the 8-week induction period, and patient-year−adjusted rates during 52 weeks.
The research team observed significant reductions in risk of all-cause, UC-related, and UC- or drug-related hospitalizations within the first 8 weeks of adalimumab therapy compared with placebo.
Significantly lower incidence rates for all-cause, UC-related, and UC- or drug-related hospitalizations were observed during 52 weeks of adalimumab therapy compared with placebo.
The team found that rates of colectomy did not differ significantly between patients given adalimumab vs placebo.
Dr Feagan's team comments, "In patients with moderate to severe UC, the addition of adalimumab to standard of care treatment reduced the number of hospitalizations for any cause, as well as for UC-related and UC- or drug-related complications, compared with placebo."